FDA 483 OBSERVATION · #816 OF 1,932 MOST-CITED

Ensuring compliance with plan and protocol

FDA cited this observation 24 times across 23 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Bioresearch Monitoring24
BY FISCAL YEAR
FY20261
FY20252
FY20242
FY20231
FY20221
FY20203
FY20192
FY20182
FY20174
FY20166

How FDA worded it — real examples

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

Filipa Lynce, M.D. · Boston, Massachusetts · Bioresearch Monitoring · 2025-10-21

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

Boehringer Ingelheim Pharmaceuticals, Inc. · Ridgefield, Connecticut · Bioresearch Monitoring · 2025-09-11

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

Shaji K. Kumar, M.D. · Rochester, Minnesota · Bioresearch Monitoring · 2025-06-20

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

Liana Apostolova, M.D. · Indianapolis, Indiana · Bioresearch Monitoring · 2024-04-18

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

GE Healthcare Inc. · Arlington Heights, Illinois · Bioresearch Monitoring · 2024-03-08

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

Anish S. Shah, M.D. · Santa Rosa, California · Bioresearch Monitoring · 2022-12-16

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

GCP discipline →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →